CANbridge Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

CANbridge Pharmaceuticals CEO'su James Qun Xue, Jan2018 tarihinde atandı, in görev süresi 6.83 yıldır. in toplam yıllık tazminatı CN¥ 9.55M olup, şirket hissesi ve opsiyonları dahil olmak üzere 59.8% maaş ve 40.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 9.85% ine doğrudan sahiptir ve bu hisseler € 667.41K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 2.8 yıldır.

Anahtar bilgiler

James Qun Xue

İcra Kurulu Başkanı

CN¥9.5m

Toplam tazminat

CEO maaş yüzdesi	59.8%
CEO görev süresi	6.8yrs
CEO sahipliği	9.9%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	2.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

James Qun Xue'un ücretlendirmesi CANbridge Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥408m
Mar 31 2024	n/a	n/a	-CN¥393m
Dec 31 2023	CN¥10m	CN¥6m	-CN¥379m
Sep 30 2023	n/a	n/a	-CN¥416m
Jun 30 2023	n/a	n/a	-CN¥453m
Mar 31 2023	n/a	n/a	-CN¥468m
Dec 31 2022	CN¥13m	CN¥5m	-CN¥483m
Sep 30 2022	n/a	n/a	-CN¥733m
Jun 30 2022	n/a	n/a	-CN¥982m
Mar 31 2022	n/a	n/a	-CN¥1b
Dec 31 2021	CN¥10m	CN¥4m	-CN¥1b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥828m
Dec 31 2020	CN¥6m	CN¥4m	-CN¥846m
Dec 31 2019	CN¥10m	CN¥3m	-CN¥218m

Tazminat ve Piyasa: James Qun 'nin toplam tazminatı ($USD 1.32M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 472.15K ).

Tazminat ve Kazançlar: James Qun 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

James Qun Xue (54 yo)

6.8yrs

Görev süresi

CN¥9,545,000

Tazminat

Dr. James Qun Xue, Ph D., M.B.A., has served as Chairman of the Board and Chief Executive Officer at CANbridge Pharmaceuticals Inc. since January 2018 and as an executive Director on June 21, 2021 and serv...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Qun Xue	Founder	6.8yrs	CN¥9.55m	9.85% € 667.4k
Qian Ma	General Counsel	3.4yrs	Veri yok	Veri yok
Stella Mao	Vice President of Public Affairs	4.8yrs	Veri yok	Veri yok
Chris Chen	Vice President of Human Resources	no data	Veri yok	Veri yok
Gerald F. Cox	Chief Development Strategist & Interim Chief Medical Officer	5.3yrs	Veri yok	Veri yok
Pauline Li	Chief Medical Officer	no data	Veri yok	Veri yok
Rebecca Zhang	Senior Vice President of Regulatory Affairs	2.3yrs	Veri yok	Veri yok
Jeff Kou	Director and Head of Program Management & Clinical Operations	2.8yrs	Veri yok	Veri yok
Fannie Man	Mainland China Commercial Head & GM of Hong Kong and Macau	1.3yrs	Veri yok	Veri yok
Jason West	Head of Global Gene Therapy Research	no data	Veri yok	Veri yok
Joe Shen	Senior Vice President	less than a year	Veri yok	Veri yok
Will Wang	Senior Director & Head of Production	no data	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim: MF1 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Qun Xue	Founder	6.8yrs	CN¥9.55m	9.85% € 667.4k
James Arthur Geraghty	Independent Non-Executive Director	6.3yrs	CN¥317.00k	0.16% € 11.2k
Peng Kuan Chan	Independent Non-Executive Director	3.4yrs	CN¥317.00k	Veri yok
Richard Gregory	Independent Non-Executive Director	4.6yrs	CN¥317.00k	Veri yok
Guangping Gao	Member of Strategic Advisory Board	4.4yrs	Veri yok	Veri yok
Mark A. Goldberg	Member of Strategic Advisory Board	no data	Veri yok	Veri yok
Anthony Amato	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Richard Polisson	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Lan Hu	Independent Non-Executive Director	2.8yrs	CN¥320.00k	Veri yok
Robert Colvin	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Jean Francis	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Sushrut Waikar	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MF1 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

CANbridge Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

CANbridge Pharmaceuticals Inc. Announces Board and Board Committee Changes

CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board

Recent updates

First half 2024 earnings released: CN¥0.58 loss per share (vs CN¥0.51 loss in 1H 2023)

CANbridge Pharmaceuticals Inc. Announces Board and Board Committee Changes

CANbridge Pharmaceuticals Inc. to Report First Half, 2024 Results on Aug 29, 2024

Full year 2023 earnings released: CN¥0.89 loss per share (vs CN¥1.14 loss in FY 2022)

CANbridge Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee

CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress

CANbridge Announces NDA Acceptance of CAN108 (???®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration

Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China

Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Algs)

First half 2023 earnings released: CN¥0.51 loss per share (vs CN¥0.59 loss in 1H 2022)

High number of new and inexperienced directors

CANbridge Pharmaceuticals Inc. to Report First Half, 2023 Results on Aug 30, 2023

CANbridge Pharmaceuticals Inc. Announces Preliminary Clinical Data of Phase 1B Study of Omoprubart (CAN106) in Paroxysmal Nocturnal Hemoglobinuria (PNH)

CANbridge Pharmaceuticals, Inc. Announces Marketing Approval of CAN108 (LIVMARLI) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

CANbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in China Region of the Global LIVMARLI(R) (CAN108) EMBARK Phase 2 Study in Biliary Atresia

Full year 2022 earnings released: CN¥1.14 loss per share (vs CN¥11.43 loss in FY 2021)

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China

High number of new and inexperienced directors

High number of new and inexperienced directors

First half 2022 earnings released: CN¥0.59 loss per share (vs CN¥46.79 loss in 1H 2021)

CANbridge Pharmaceuticals Inc. to Report First Half, 2022 Results on Aug 24, 2022

Canbridge Pharmaceuticals Inc. Announces First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China

CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board

Canbridge Pharmaceuticals Inc. Announces Board Changes

High number of new and inexperienced directors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş